✦ LIBER ✦

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

✍ Scribed by Reeder, C B; Reece, D E; Kukreti, V; Chen, C; Trudel, S; Hentz, J; Noble, B; Pirooz, N A; Spong, J E; Piza, J G

Book ID: 109887012
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 141 KB
Volume: 23
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2009.26

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lenalidomide, cyclophosphamide and dexam

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

✍ Shaji K. Kumar; Martha Q. Lacy; Suzanne R. Hayman; Keith Stewart; Francis K. Bua 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

Bortezomib, dexamethasone, cyclophospham

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

✍ Kumar, S K; Flinn, I; Noga, S J; Hari, P; Rifkin, R; Callander, N; Bhandari, M; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 302 KB

Phase II clinical trial of arsenic triox

Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma

✍ C.C. Hofmeister; B. Jansak; N. Denlinger; E.H. Kraut; D.M. Benson; S.S. Farag 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 90 KB

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As 2 O 3 ) with DVd (Doxil TM , vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followe

A steroid-independent regimen of bortezo

A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

✍ Taimur Sher; Sikander Ailawadhi; Kena C. Miller; Debbie Manfredi; Margaret Wood; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB

A Phase II trial of pegylated liposomal

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients

✍ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop